Overview

Anecortave Acetate Risk-Reduction Trial (AART)

Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.
Phase:
Phase 3
Details
Lead Sponsor:
Alcon Research
Treatments:
Anecortave
Hydrocortisone